Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-08-24, Stock:LLY, The news for the past five days is as follows:
2018-08-17: NEWS1: Should you trade or fade this week's biggest winners?.NEWS2: Lilly (LLY) Hits 52-Week High, Can the Run Continue?.NEWS3: Lilly (LLY) Hits 52-Week High, Can the Run Continue?.NEWS4: Pharma Stock Roundup: Blow for Bayer, FDA Nod for MRK Cancer Drug in New Indication.NEWS5: Pharma Stock Roundup: Blow for Bayer, FDA Nod for MRK Cancer Drug in New Indication.NEWS6: Lilly (LLY) Hits 52-Week High, Can the Run Continue?.NEWS7: The Daily Biotech Pulse: Aveo Slips On Stock Offering, FDA Greenlights Generic EpiPen, Pfenex Exec Resigns.
2018-08-20: NEWS1: Amgen’s Product Performance in Q2 2018.NEWS2: Drugmakers Extend Summer Rally as Markets Regain Footing.NEWS3: Allergan’s US General Medicines Segment in Q2 2018.NEWS4: Non-Opioid Pain Therapy Market Opportunity for Teva.
2018-08-21: NEWS1: Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?.NEWS2: Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?.NEWS3: Merck Gets FDA Nod for Keytruda Lung Cancer Label Expansion.NEWS4: Merck Gets FDA Nod for Keytruda Lung Cancer Label Expansion.NEWS5: Merck Gets FDA Nod for Keytruda Lung Cancer Label Expansion.NEWS6: A Look at Teva Pharmaceutical’s Valuation Multiples in August.NEWS7: Recent Developments at Allergan.
2018-08-22: NEWS1: Incyte’s Revenue Stream in Q2 2018.NEWS2: Allergan Falls on FDA's Rejection of Uterine Fibroids Drug.NEWS3: Allergan Falls on FDA's Rejection of Uterine Fibroids Drug.NEWS4: IXJ, BMY, LLY, TMO: ETF Outflow Alert.NEWS5: IXJ, BMY, LLY, TMO: ETF Outflow Alert.NEWS6: Considering Incyte’s Revenue Trend in Q2 2018.NEWS7: Allergan Falls on FDA&apos;s Rejection of Uterine Fibroids Drug.
2018-08-23: NEWS1: Pfizer Amends Xtandi Study Protocols to Speed Up Completion.NEWS2: Pfizer Amends Xtandi Study Protocols to Speed Up Completion.NEWS3: J&J to Appeal as Judge Confirms Jury Order in Talc Case.NEWS4: J&J to Appeal as Judge Confirms Jury Order in Talc Case.NEWS5: Pfizer Amends Xtandi Study Protocols to Speed Up Completion.NEWS6: J&J to Appeal as Judge Confirms Jury Order in Talc Case.NEWS7: Large-Cap Pharma Rebounds: 2 Stocks to Boost Your Portfolio.NEWS8: Large-Cap Pharma Rebounds: 2 Stocks to Boost Your Portfolio.NEWS9: Xtandi Trials: Pfizer and Astella Amend the Protocols.NEWS10: Large-Cap Pharma Rebounds: 2 Stocks to Boost Your Portfolio.NEWS11: How Incyte’s Product Portfolio Is Looking in August.

Answer: Rise